Unavailable
Unavailable
Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl
SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)
424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)
S-1 - Adagio Medical Holdings, Inc. (0002006986) (Filer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)